Transgene Biotek Intrinsic Value
Transgene Biotek (TRABI) median intrinsic value is ₹1.05 from 1 valuation models (range ₹1–₹1), vs current price ₹2.98 — -64.8% downside (Trading Above Calculated Value), margin of safety -100.0%. Read TRABI dividend growth for the complete payout history and dividend yield track record.
TRABI Valuation Methods Summary — DCF, Graham Number & P/E
Transgene Biotek intrinsic value across 1 models vs current price ₹2.98 — upside/downside and value range per method. Analyse TRABI shareholder distribution to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹1.05 | ₹0.95 - ₹1.16 | -64.8% | Book Value/Share: ₹1.05, P/B: 1.0x |
TRABI Intrinsic Value vs Market Price — All Valuation Models
Transgene Biotek fair value range ₹1–₹1 vs current market price ₹2.98 across 1 valuation models. For current market price and key ratios, visit TRABI share price screener.
TRABI Intrinsic Value Analysis — Undervalued or Overvalued?
Transgene Biotek median intrinsic value ₹1.05, current price ₹2.98 — Trading Above Calculated Value by 64.8%, margin of safety -100.0%.
What is the intrinsic value of TRABI?
Based on our comprehensive analysis using 1 different valuation methods, the estimated intrinsic value of Transgene Biotek (TRABI) is ₹1.05 (median value). With the current market price of ₹2.98, this represents a -64.8% variance from our estimated fair value.
The valuation range spans from ₹1.05 to ₹1.05, indicating ₹1.05 - ₹1.05.
Is TRABI undervalued or overvalued?
Based on our multi-method analysis, Transgene Biotek (TRABI) appears to be trading above calculated value by approximately 64.8%.
TRABI Financial Health — Key Ratios vs Industry Benchmarks
Transgene Biotek financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.01 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | -50.0% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -560.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
TRABI Cash Flow Quality — Operating & Free Cash Flow
Transgene Biotek operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1 Cr | ₹0 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |